Gilead Sciences Inc. (NASDAQ:GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial.The open-label trial evaluated the treatment responses of HIV patients who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). • GILD shares are testing new highs. Check the market position here.In ARTISTRY-1, the once-daily single-tablet regimen of BIC/LEN met the primary success criterion for non ...